Omnia Signs Drug Development Agreement With AparnaBio

Omnia Biologics (Omnia) and Aparna Biosciences (AparnaBio) has signed a deal for Omnia to provide AparnaBio with process development and production services. Omnia will provide lentiviral vector technical services as well as manufacture of research grade through cGMP grade materials.

Dale VanderPutten, CEO of Omnia, said: “Despite recent setbacks in lentivirus based drug development on the business side, we continue to see great promise in the platform. We are pleased to be chosen by AparnaBio as a partner in this development effort.”

Omnia is a contract manufacturer focused on process development and clinical trials material manufacturing of innovative biopharmaceuticals.

AparnaBio is developing a new class of proprietary nanomedicine drug delivery technology.